Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05975489
Other study ID # UFV_genetic_caffeine
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2020
Est. completion date April 1, 2022

Study information

Verified date July 2022
Source Universidad Francisco de Vitoria
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Genetic polymorphism on the effect of oral caffeine intake on fat oxidation during exercise has been studied in active and healthy population performing an incremental test on a cycle ergometer with 3-min stages at workloads from 30 to 70% of maximal oxygen uptake (VO2max). Participants performed this test after the ingestion of a) placebo; b) 3 mg/kg of caffeine; c) 6 mg/kg of caffeine. Fat oxidation rate during exercise was measured by indirect calorimetry. The influence of the CYP1A2 c.-163A>C, GSTP c.313A>G and PGC1a polymorphisms was evaluated to determine the effects on fat oxidation during exercise


Description:

Caffeine is a natural stimulant with well-recognized sports performance benefits. Aside its performance-enhancing effect, caffeine has the potential of increasing fat utilization during aerobic exercise at submaximal intensities, lowering-down the contribution of carbohydrate as a fuel. This property of caffeine may provoke a glycogen-sparing effect in the skeletal muscle and liver for exercise situations where carbohydrate availability may be a challenge. Additionally, the capacity of caffeine to enhance fat utilization during exercise could be of interest for improving health outcomes as it may increase the rate of change in body composition in exercise programs. Genetic factors like CYP1A2 c.-163A>C, GSTP c.313A>G and PGC1a c.1444G>A and C>T polymorphisms could be associated with the capacity for fat oxidation during exercise. To date, it is unknown if genetics increases fat oxidation and MFO in the same proportion during morning and evening exercise trials in women. For this reason, the aim of the present study was to evaluate the influence of the tCYP1A2, GSTP and PGC1a polymorphisms on the effect of caffeine on fat oxidation and MFO in active and healthy population. The authors hypothesised that genetics would increase fat oxidation and MFO during exercise and this effect would be of similar magnitude at several caffeine doses.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date April 1, 2022
Est. primary completion date February 10, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: To be non-smokers. To have low caffeine intake (i.e., < 50 mg of caffeine per day in the previous 2 months) To show no previous history of cardiopulmonary diseases or having suffered musculoskeletal injuries in the previous 6 months. Exclusion Criteria: To have VO2max values below 40 ml/kg/min To be sedentary

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Acute caffeine supplementation
To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women

Locations

Country Name City State
Spain Universidad Francisco de Vitoria Pozuelo De Alarcón Madrid

Sponsors (1)

Lead Sponsor Collaborator
Universidad Francisco de Vitoria

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Genotype frequency of CYP1A2 polymorphism Samples shall be obtained by swabbing and scraping of the buccal mucosa by the participant. The c.-163A>C (rs762551) polymorphism will be used. Baseline
Primary Genotype frequency of GSTP polymorphism Samples shall be obtained by swabbing and scraping of the buccal mucosa by the participant. The c.1444G>A (rs8192678) and C>T (rs17650401) polymorphisms will be used. Baseline
Primary Genotype frequency of PGC1a polymorphisms Samples shall be obtained by swabbing and scraping of the buccal mucosa by the participant. The c.313A>G (rs1695) polymorphism will be used. Baseline
Secondary FATmax The intensity of exercise that elicits MFO 2-months
Secondary MFO Maximal fat oxidation during exercise 2-months
Secondary RPE Rate of percevied exertion during exercise 2-months
Secondary FAT and CHO oxidation Fat and carbohydrates oxidation 2-months
See also
  Status Clinical Trial Phase
Completed NCT04746794 - Early Detection of GEnetic Risk (EDGE) N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Recruiting NCT04970056 - Pancreatic Cancer Early Detection Consortium
Not yet recruiting NCT06441942 - Prospective Multicenter Registry of Gender, Diversity and Inclusion (GEDI) of Women With Acute Coronary Syndrome
Terminated NCT04119596 - Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
Recruiting NCT04141462 - EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer N/A
Completed NCT02826330 - Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease
Recruiting NCT05929976 - InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
Not yet recruiting NCT04620278 - Genetic Investigation of Cancer Predisposition
Active, not recruiting NCT02373709 - Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression
Not yet recruiting NCT06089421 - Genetic Information Assistant in Telegenetics N/A
Completed NCT03954652 - Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH" N/A
Completed NCT04113239 - Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus
Enrolling by invitation NCT04373525 - Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users
Completed NCT03362099 - Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING) Phase 4
Recruiting NCT05857670 - Psyco Quality of Life and Procreation BRCA1/2
Active, not recruiting NCT04774445 - Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes N/A
Recruiting NCT05759143 - Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing N/A
Active, not recruiting NCT04920513 - Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.
Active, not recruiting NCT04781205 - Genome Driven Primary Care Clinics - an RCT N/A